752 related articles for article (PubMed ID: 31519403)
1. Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention.
Osibogun O; Ogunmoroti O; Michos ED
Trends Cardiovasc Med; 2020 Oct; 30(7):399-404. PubMed ID: 31519403
[TBL] [Abstract][Full Text] [Related]
2. Polycystic ovary syndrome: a "risk-enhancing" factor for cardiovascular disease.
Guan C; Zahid S; Minhas AS; Ouyang P; Vaught A; Baker VL; Michos ED
Fertil Steril; 2022 May; 117(5):924-935. PubMed ID: 35512976
[TBL] [Abstract][Full Text] [Related]
3. Subclinical cardiovascular disease and polycystic ovary syndrome.
Gomez JMD; VanHise K; Stachenfeld N; Chan JL; Merz NB; Shufelt C
Fertil Steril; 2022 May; 117(5):912-923. PubMed ID: 35512975
[TBL] [Abstract][Full Text] [Related]
4. The cardiovascular risk profile of middle-aged women with polycystic ovary syndrome.
Meun C; Gunning MN; Louwers YV; Peters H; Roos-Hesselink J; Roeters van Lennep J; Rueda Ochoa OL; Appelman Y; Lambalk N; Boersma E; Kavousi M; Fauser BC; Laven JS;
Clin Endocrinol (Oxf); 2020 Feb; 92(2):150-158. PubMed ID: 31638273
[TBL] [Abstract][Full Text] [Related]
5. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society.
Wild RA; Carmina E; Diamanti-Kandarakis E; Dokras A; Escobar-Morreale HF; Futterweit W; Lobo R; Norman RJ; Talbott E; Dumesic DA
J Clin Endocrinol Metab; 2010 May; 95(5):2038-49. PubMed ID: 20375205
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Evaluation of Type 2 Diabetes and Cardiovascular Disease Risk Profiles in Reproductive-Age Women with Polycystic Ovary Syndrome: A Large Canadian Cohort.
Kazemi M; Pierson RA; Lujan ME; Chilibeck PD; McBreairty LE; Gordon JJ; Serrao SB; Zello GA; Chizen DR
J Obstet Gynaecol Can; 2019 Oct; 41(10):1453-1460. PubMed ID: 30712903
[TBL] [Abstract][Full Text] [Related]
7. Cardiometabolic risks in PCOS: a review of the current state of knowledge.
Kakoly NS; Moran LJ; Teede HJ; Joham AE
Expert Rev Endocrinol Metab; 2019 Jan; 14(1):23-33. PubMed ID: 30556433
[TBL] [Abstract][Full Text] [Related]
8. The cardiometabolic effect of current management of polycystic ovary syndrome: strategies of prevention and treatment.
Baldani DP; Skrgatic L; Ougouag R; Kasum M
Gynecol Endocrinol; 2018 Feb; 34(2):87-91. PubMed ID: 28944709
[TBL] [Abstract][Full Text] [Related]
9. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease.
Meyer C; McGrath BP; Teede HJ
J Clin Endocrinol Metab; 2005 Oct; 90(10):5711-6. PubMed ID: 16046590
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Risk in Postmenopausal Women with Polycystic Ovary Syndrome.
Armeni E; Lambrinoudaki I
Curr Vasc Pharmacol; 2019; 17(6):579-590. PubMed ID: 30156159
[TBL] [Abstract][Full Text] [Related]
11. The effects of exercise on cardiometabolic outcomes in women with polycystic ovary syndrome not taking the oral contraceptive pill: protocol for a systematic review and meta-analysis.
Woodward A; Klonizakis M; Lahart I; Carter A; Dalton C; Metwally M; Broom D
Syst Rev; 2019 May; 8(1):116. PubMed ID: 31097035
[TBL] [Abstract][Full Text] [Related]
12. Polycystic Ovary Syndrome.
Azziz R
Obstet Gynecol; 2018 Aug; 132(2):321-336. PubMed ID: 29995717
[TBL] [Abstract][Full Text] [Related]
13. Polycystic ovarian syndrome.
Khan KA; Stas S; Kurukulasuriya LR
J Cardiometab Syndr; 2006; 1(2):125-30; quiz 131-2. PubMed ID: 17679815
[TBL] [Abstract][Full Text] [Related]
14. Obese adolescents with polycystic ovarian syndrome have elevated cardiovascular disease risk markers.
Patel SS; Truong U; King M; Ferland A; Moreau KL; Dorosz J; Hokanson JE; Wang H; Kinney GL; Maahs DM; Eckel RH; Nadeau KJ; Cree-Green M
Vasc Med; 2017 Apr; 22(2):85-95. PubMed ID: 28095749
[TBL] [Abstract][Full Text] [Related]
15. Polycystic Ovary Syndrome, Insulin Resistance, and Cardiovascular Disease.
Dubey P; Reddy S; Sharma K; Johnson S; Hardy G; Dwivedi AK
Curr Cardiol Rep; 2024 Jun; 26(6):483-495. PubMed ID: 38568339
[TBL] [Abstract][Full Text] [Related]
16. The metabolic syndrome in women: a growing problem for cardiac risk.
Paul S; Smith L
J Cardiovasc Nurs; 2005; 20(6):427-32. PubMed ID: 16485627
[TBL] [Abstract][Full Text] [Related]
17. Is There Really Increased Cardiovascular Morbidity in Women with Polycystic Ovary Syndrome?
Carmina E; Lobo RA
J Womens Health (Larchmt); 2018 Nov; 27(11):1385-1388. PubMed ID: 30199308
[TBL] [Abstract][Full Text] [Related]
18. Hemostatic abnormalities and relationships to metabolic and hormonal status in polycystic ovarian syndrome.
Burchall G; Linden MD; Teede H; Piva TJ
Trends Cardiovasc Med; 2011 Jan; 21(1):6-14. PubMed ID: 22498014
[TBL] [Abstract][Full Text] [Related]
19. Polycystic ovary syndrome and metabolic syndrome.
Ali AT
Ceska Gynekol; 2015 Aug; 80(4):279-89. PubMed ID: 26265416
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular disease risk in first-degree relatives of women with polycystic ovary syndrome.
Vipin VP; Dabadghao P; Shukla M; Kapoor A; Raghuvanshi AS; Ramesh V
Fertil Steril; 2016 May; 105(5):1338-1344.e3. PubMed ID: 26852421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
